MOG and myeloid sarcoma: This overview highlights key variations in terms of the presence of the T2/FLAIR mismatch sign, contrast enhancement, mass effect, additional demyelinating MS foci, response to steroids and biopsy, and laboratory findings such as oligoclonal bands and MOG-IgG seropositivity.